NXTS Nexentis Technologies Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1789192 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY18.6%
TTM net income YoY-19.7%
TTM EPS YoY-31,123.8%
Revenue 3-yr CAGR-16.6%
Net income 3-yr CAGR—
Margins
Gross margin65.2%
Operating margin-2,119.7%
Net margin-3,187.1%
FCF margin—
EBITDA margin-2,114.4%
Returns
ROE-92.5%
ROA-78.9%
ROIC (approx.)-126.3%
Asset turnover0.02x
Leverage & solvency
Liabilities / assets21.3%
Debt / equity0.00x
Current ratio4.21x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.42x
Accruals ratio-45.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q2*2025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | $2,000 | $0 | $66,000 | $140,519 |
| Cost of revenue | — | — | — | — | $2,000 | $2,000 | $14,000 | $54,477 |
| Gross profit | — | — | — | — | $0 | -$2,000 | $52,000 | $86,042 |
| R&D expense | $288,000 | $373,000 | $275,000 | $98,000 | $52,000 | $9,000 | $20,000 | $119,034 |
| SG&A expense | $985,000 | $1.26M | $1.90M | $492,000 | $1.07M | $2.63M | $503,000 | $477,000 |
| Operating income | -$1.23M | -$1.88M | -$8.22M | $549,000 | -$1.07M | -$2.63M | -$503,000 | -$219,000 |
| Pretax income | $4.98M | -$11.18M | -$7.45M | $1.27M | $616,000 | -$4.39M | -$1.12M | — |
| Income tax | -$24,000 | -$23,000 | -$23,000 | — | — | — | — | — |
| Net income | $5.03M | -$11.14M | -$6.58M | $1.27M | $429,000 | -$4.51M | -$1.19M | -$1.37M |
| EBITDA | -$1.13M | -$1.77M | -$8.14M | $612,000 | -$1.07M | -$2.62M | -$500,000 | -$215,957 |
| EPS (basic) | 17.12 | -13.66 | -10.74 | — | 15.47 | -44.26 | -18.00 | — |
| EPS (diluted) | -0.29 | -13.66 | -10.74 | — | 11.59 | -44.26 | -85.25 | — |
| Weighted avg. shares (diluted) | 482,401 | 816,136 | 612,715 | — | 28,432 | 101,862 | 101,975 | — |
| Banking | ||||||||
| Net interest income | — | — | — | — | — | $127,000 | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $2.84M | $7.62M | $4.30M | $3.83M | $6.07M | $3.16M | $2.75M | $2.21M |
| Short-term investments | $640,000 | $1.26M | $1.90M | $239,000 | $240,000 | $271,000 | $230,000 | $307,000 |
| Receivables | — | — | $130,000 | $134,000 | $2,000 | $195,000 | $195,000 | $137,000 |
| Inventory | — | — | — | — | $16,000 | $16,000 | $15,000 | $21,000 |
| Current assets | $7.64M | $10.39M | $8.22M | $6.01M | $8.66M | $5.02M | $4.33M | $3.45M |
| PP&E, net | $82,000 | $86,000 | $89,000 | $26,000 | $40,000 | $43,000 | $45,000 | $48,000 |
| Goodwill | — | — | — | $6.29M | — | — | — | — |
| Intangibles | $4.12M | $4.23M | $4.33M | $4.43M | — | — | — | — |
| Total assets | $15.49M | $18.69M | $16.40M | $20.41M | $11.03M | $7.75M | $7.37M | $5.46M |
| Current liabilities | $1.96M | $2.80M | $1.74M | $1.43M | $2.06M | $1.06M | $976,000 | $892,000 |
| Short-term debt | — | $215,000 | $364,000 | $740,000 | $1.22M | $1.23M | $651 | — |
| Total liabilities | $2.72M | $16.91M | $3.54M | $4.67M | $2.35M | $2.20M | $3.67M | $892,000 |
| Shareholders' equity | $12.90M | $1.91M | $12.97M | $16.01M | $8.93M | $5.76M | $3.94M | $4.75M |
| Shares outstanding | 297,885 | 1.45M | 730,459 | 79,504 | 1.37M | 30.10M | 17.81M | 344,741 |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.23M | -$539,000 | -$1.42M | -$1.50M | -$974,000 | -$528,000 | -$809,000 | -$491,852 |
| Capital expenditure | $0 | $1,000 | $71,000 | — | — | — | — | — |
| Free cash flow | -$1.23M | -$540,000 | -$1.49M | — | — | — | — | — |
| Investing cash flow | -$2.79M | -$110,000 | -$450,000 | -$1.33M | -$273,000 | -$449,000 | -$1.18M | -$515,956 |
| Financing cash flow | -$770,000 | $3.95M | $2.20M | $759,000 | $4.16M | $1.40M | $2.53M | $445,968 |
| Depreciation & amortization | $107,000 | $106,000 | $82,000 | $63,000 | $3,000 | $2,000 | $3,000 | $3,043 |
| Stock-based compensation | $217,000 | $70,000 | $90,000 | $90,000 | $0 | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.